Drug firm Venus Remedies has received approvals from health authorities in the UK and New Zealand for marketing its generic injectable antibiotic Meropenem which is used for treating bacterial infections. The company has received approvals from Medicines and Healthcare products Regulatory Agency (MHRA) UK and New Zealand Ministry of Health for its generic Meropenem.
The drug will be launched in this fiscal year. Meropenem sales account for USD 906 million across the globe, which is estimated to grow to USD 1,006 million by 2012. The company is already selling the drug in various markets and is in the process of extending its sales in other regulated markets.
